Achillion Pharmaceuticals

Latest Headlines

Latest Headlines

UPDATED: Buoyed by 6-week hep C data, Achillion sets out to test even faster cure

While Regulus was getting dinged this morning following some careful scrutiny of its latest hep C data, Achillion came out on top with new trial results which demonstrated that a combination of its NS5A inhibitor and Gilead's Sovaldi triggered a 6-week cure among all of the patients in a small study. And now researchers are using the data to set the stage to see if the results can be replicated even faster in a 4-week trial.

Achillion shoulders its way into the hep C race with strong early data

Biotech Achillion Pharmaceuticals is working to get its name on the short list of blockbuster hepatitis C contenders, revealing promising Phase II data for a combination of its antiviral with Gilead Sciences' leading Sovaldi.

Achillion soars (again) as FDA lifts a hold and hep C returns to the spotlight

Few biotechs loved to flirt with investors about the prospect of a buyout more than the hepatitis C specialist Achillion. Former CEO Michael Kishbauch made a habit of it. And not long after Milind Deshpande took the helm last fall, he quickly reignited talk of a sale, only to watch the stock tank days later when the FDA put its NS3/4A protease inhibitor, sovaprevir, on clinical hold.

Achillion shares crushed in a rout as hep C blockbuster hopes fade

After the market closed on Friday, Achillion spread the word that the FDA is maintaining its clinical hold related to its once-hot hepatitis C drug sovaprevir, while distributing some unimpressive data on its combination approach.

Achillion shares skid lower after FDA puts a hold on hep C drug

Shares of Achillion skidded down 20% as the news spread Monday evening that the FDA put a clinical hold on its hepatitis C drug sovaprevir after investigators flagged a spike in liver enzymes--a classic sign of toxicity--among a group of patients taking it in a combo treatment.

Bristol-Myers, Achillion, Idenix show progress with oral hepatitis C drugs

Bristol-Myers Squibb is staying in the chase to commercialize an all-oral regimen for hepatitis C, despite having to end development of one of its key weapons against the liver-damaging disease this summer because of serious adverse events in study patients.

Achillion heralds upbeat hepatitis C results as it rushes through Phase II

A year ago buzz about a potential Achillion buyout was all the rage as big biopharma rivals jostled for the inside track in a multibillion-dollar race through the clinic with next-gen hepatitis C therapies.

Achillion Pharma strikes deal to raise $41.8M as hep C results loom

Hepatitis C drug developer Achillion Pharmaceuticals expects to haul in proceeds of a $41.8 million sale of common stock to QVT Financial. And the funding comes ahead of some important clinical trial results from the New Haven, CT-based developer's pipeline of hep C treatments.

Achillion Pharma attracts buyout buzz as hep C rivals fall

With developers of oral hepatitis C drugs falling hard in recent weeks, Achillion Pharmaceuticals has attracted fresh M&A speculation because the developer's contenders in this closely watched race remain unscathed in clinical studies.

Achillion burnishes buyout prospects, snags fast track for hep C drug

Achillion CEO Michael Kishbauch hasn't been the least bit shy about touting the company's buyout prospects. Quick to boast about the biotech's promising hepatitis C drugs, he's been raising hopes and stirring buyout buzz with every appearance.